Surrozen, Inc./DE (NASDAQ: SRZNW)

Surrozen, Inc./DE, a clinical-stage biotechnology company, is dedicated to transforming the treatment of serious diseases by fully exploiting the Wnt pathway, a critical mediator of tissue repair in a broad range of organs and tissues. Surrozen is headquartered in South San Francisco, California, and its mission is to develop a portfolio of product candidates that can activate Wnt signaling only within targeted diseased tissue, focusing on severe diseases, and mimicking the self-limiting physiologic repair process.

Surrozen's main business activities revolve around discovering and developing drug candidates to selectively modulate the Wnt pathway. The company operates in the biotechnology industry and conducts its research and development activities primarily in the United States. Surrozen's Wnt therapeutics platform is based on the company's breakthrough discoveries and technologies, which enable the design and development of potent, selective, and manufacturable Wnt and R-spondin mimetics. The company's platform technologies, SWAP and SWEETS, are designed to mimic the activity of naturally occurring Wnt proteins and R-spondin, respectively.

Surrozen generates revenue through the development of its proprietary Wnt therapeutics platform and product candidates. The company's primary products include SZN-043 and SZN-413, which are being developed using the company's proprietary SWAP and SWEETS technologies, respectively. SZN-043 is a hepatocyte-specific R-spondin mimetic bispecific fusion protein that has shown promising results in preclinical models of liver injury and fibrosis. The company is currently conducting a Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis.

SZN-413, on the other hand, is a Fzd4 targeted bi-specific antibody that is being developed for the treatment of retinal vascular-associated diseases. Surrozen has executed a collaboration and licensing agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies designed using Surrozen's SWAP technology.

Surrozen's position within the industry is strengthened by its proprietary technologies, SWAP and SWEETS, which enable the design and development of potent, selective, and manufacturable Wnt and R-spondin mimetics. The company's Wnt therapeutics platform has shown promising results in preclinical models of various diseases, and its lead product candidates are being developed for the treatment of liver injury and fibrosis and retinal vascular-associated diseases, respectively.

Surrozen's customers include Boehringer Ingelheim International GmbH, which has executed a collaboration and licensing agreement with the company to research, develop, and commercialize Fzd4 bi-specific antibodies designed using Surrozen's SWAP technology. The company may also enter into collaborations and licensing agreements with other pharmaceutical companies and research organizations to develop and commercialize its product candidates.

Surrozen's brand names and/or trade names of its products and services include SZN-043, SZN-413, SWAP, and SWEETS. These names reflect the company's commitment to developing innovative therapies for serious diseases by fully exploiting the Wnt pathway.